Devonian Health Group Inc.

Devonian Health Group Inc. develops botanical drugs. The company's primary product candidate is Thykamine, which is undergoing several clinical trials: a phase 3 clinical trial for treating Atopic dermatitis in adults, a phase 2/3 clinical trial for Atopic dermatitis in children, a phase 2 clinical trial for Hand-Foot Syndrome (HFS) associated with chemotherapy, a phase 2/3 clinical trial for Radiodermatitis associated with radiotherapy, and a phase 2a clinical trial for ulcerative colitis. Devonian Health Group Inc. also develops Pantoprazole Magnesium for gastric reflux treatment and Cleo-35 for hormonal acne in women. Additionally, the company offers R-Spinasome anti-aging cream, serum, and regenerating creams, as well as anti-aging products under the Purgenesis brand, which include day, night, and eye creams. Devonian Health Group Inc. is based in Québec, Canada.